Pierre Fabre Set To Shake Up EU Melanoma Market
Executive Summary
Having just got the nod for the combination of Braftovi and Mektovi, the French company believes the strength of its overall survival data will see the therapy successfully compete with other BRAF/MEK combos and immunotherapies for melanoma.
You may also be interested in...
Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
UK NICE OKs Melanoma Combo Treatment From Array/Pierre Fabre
Array BioPharma/Pierre Fabre’s combination treatment for metastatic melanoma has received NICE's go-ahead for funding under the national health service in England and Wales.
Array Celebrates BEACON Of Hope For Anti-BRAF/MEK/EGFR Triplet In Colorectal Cancer
New data on Array BioPharma's encorafenib and binimetinib together with cetuximab add hopes for its future in colorectal cancer. Recent strong data in melanoma for the BRAF/MEK combo are expected to be followed by its first US approval in the coming days.